Athira Pharma, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Operating expenses: | ||||
| Research and development | $2,825 | $17,922 | $10,788 | $61,312 |
| General and administrative | 4,049 | 7,572 | 12,913 | 19,897 |
| Legal expense | — | 4,127 | — | 4,127 |
| Total operating expenses | 6,874 | 29,621 | 23,701 | 85,336 |
| Loss from operations | (6,874) | (29,621) | (23,701) | (85,336) |
| Other income, net | 263 | 880 | 981 | 3,399 |
| Net loss | $(6,611) | $(28,741) | $(22,720) | $(81,937) |
| Unrealized (loss) gain on available-for-sale securities | 1 | 41 | (3) | 352 |
| Comprehensive loss attributable to common stockholders | $(6,610) | $(28,700) | $(22,723) | $(81,585) |
| Net loss per share attributable to common stockholders, basic and diluted | $(1.68) | $(7.46) | $(5.80) | $(21.33) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (1) | 3,943,887 | 3,851,758 | 3,919,258 | 3,840,669 |
(1) The Company effected a reverse stock split of its outstanding shares of common stock on September 17, 2025 where every ten shares of its common stock issued and outstanding was converted into one shareof common stock. Any fractional post-split shares as a result of the reverse stock split were rounded down to the nearest whole post-split share. Stockholders of the Company previously authorized the Board of Directors to approve a reverse stock split at the Company's annual meeting on May 29, 2025. All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the reverse stock split on a retroactive basis in all periods presented.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.